How to select a nanosimilar

Annals of the New York Academy of Sciences

Volumn 1407, Issue 1, 2017, Pages 50-62

  Astier, Alain ^a   Barton Pai, Amy ^b   Bissig, Marco ^c   Crommelin, Daan J A ^d   Flühmann, Beat ^e   Hecq, Jean Daniel ^f   Knoeff, Josefien ^e,g   Lipp, Hans Peter ^h   Morell Baladrón, Alberto ⁱ   Mühlebach, Stefan ^e,j  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY OF MICHIGAN   (United States)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d UTRECHT UNIVERSITY   (Netherlands)

^e Vifor (International) Inc   (Switzerland)

^f UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^g VU UNIVERSITY AMSTERDAM   (Netherlands)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j UNIVERSITY OF BASEL   (Switzerland)

more..

Author keywords

hospital formulary; interchange; nanomedicines; nanosimilars; substitution

Indexed keywords

BIOSIMILAR AGENT; NANOPARTICLE; GENERIC DRUG;

ARTICLE; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STORAGE; DRUG UPTAKE; HUMAN; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHARMACIST; PUBLIC POLICY; PUBLICATION; SHELF LIFE; SURFACE PROPERTY; THERAPEUTIC EQUIVALENCE; ALGORITHM; DRUG APPROVAL; DRUG SURVEILLANCE PROGRAM; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ALGORITHMS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUGS, GENERIC; GUIDELINES AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; NANOMEDICINE; PHARMACOVIGILANCE; THERAPEUTIC EQUIVALENCY;

EID: 85024483528     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13382     Document Type: Article

References (42)

1. Noorlander, C.W., M.W. Kooi, A.G. Oomen, et al. 2015. Horizon scan of nanomedicinal products. Nanomedicine 10: 1599–1608.
2. Ehmann, F. & R. Pita. 2016. The EU is ready for non-biological complex medicinal products. GaBI. 5: 1–6.
3. Crommelin, D.J.A. 2015. Non-biological complex drugs. In AAPS Advances in the Pharmaceutical Sciences Series. J.S.B. de Vlieger, Ed. New York: AAPS/Springer.
4. Ehmann, F., K. Sakai-Kato, R. Duncan, et al. 2013. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond.) 8: 849–856.
5. Rottembourg, J.B., A. Kadri, E. Leonard, et al. 2011. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant. 26: 3262–3267.
6. Agüera, M.L., A. Martin-Malo, M.A. Alvarez-Lara, et al. 2015. Efficiency of original versus generic intravenous iron formulations in patients on haemodialysis. PLoS One 10: e0135967.
7. Lee, E.S., B.R. Park, J.S. Kim, et al. 2013. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr. Med. Res. Opin. 29: 141–147.
8. Stein, J., A. Dignass & K.U. Chow. 2012. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr. Med. Res. Opin. 28: 241–243.
9. Martin-Malo, A., A. Merino, J. Carracedo, et al. 2012. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 27: 2465–2471.
10. European Medicines Agency. 2015. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. March 26, 2015. Accessed January 4, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184922.pdf.
11. European Medicines Agency. 2013. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. February 21, 2013. Accessed January 4, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140351.pdf.
12. U.S. Food and Drug Administration. 2015. Liposome drug products—guidance for industry. October, 2015. Accessed January 4, 2017. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070570.pdf.
13. European Medicines Agency. 2014. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. December 18, 2014. Accessed January 4, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf.
14. European Medicines Agency. 2014. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. May 22, 2014. Accessed January 4, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf.
15. Knoeff, J., B. Flühmann & S. Mühlebach. 2017. Medication practice in hospitals: are nanosimilars evaluated and substituted correctly? Eur. J. Hosp. Pharm. https://doi.org/10.1136/ejhpharm-2016-001059.
16. Schellekens, H., S. Stegemann, V. Weinstein, et al. 2014. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J. 16: 15–21.
17. Griffith, N., A. McBride, J.G. Stevenson, et al. 2014. Formulary selection criteria for biosimilars: considerations for US Health-System Pharmacists. Hosp. Pharm. 49: 813–825.
18. Boone, N., H.V.D. Kuy, M. Scott, et al. 2013. How to select a biosimilar. Eur. J. Hosp. Pharm. 20: 275–286.
19. Epstein-Barash, H., D. Gutman, E. Markovsky, et al. 2010. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J. Control. Release 146: 182–195.
20. Storm, G., S.O. Belliot, T. Daemen, et al. 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17: 31–48.
21. Doane, T.L. & C. Burda. 2012. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem. Soc. Rev. 41: 2885–2911.
22. Moghimi, S.M., C.A. Hunter & J.C. Murray. 2005. Nanomedicine: current status and future prospects. FASEB J. 19: 311–330.
23. Hirn, S., M. Semmler-Behnke, C. Schleh, et al. 2011. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. Biopharm. 77: 407–416.
24. Cheng, Y., A.C. Samia, J.D. Meyers, et al. 2008. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J. Am. Chem. Soc. 130: 10643–10647.
25. Chertow, G.M., P.D. Mason, O. Vaage-Nilsen, et al. 2004. On the relative safety of parenteral iron formulations. Nephrol. Dial. Transplant. 19: 1571–1575.
26. Bailie, G.R. 2012. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am. J. Health Syst. Pharm. 69: 310–320.
27. Heurtault, B., P. Saulnier, B. Pech, et al. 2003. Physico-chemical stability of colloidal lipid particles. Biomaterials 24: 4283–4300.
28. Geisser, P. & S. Burckhardt. 2011. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3: 12–33.
29. Brookhart, M.A., J.K. Freburger, A.R. Ellis, et al. 2013. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J. Am. Soc. Nephrol. 24: 1151–1158.
30. Pai, A.B., D. Pharm, A.V. Boyd, et al. 2007. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 27: 343–350.
31. Smith, J.A., L. Mathew, M. Burney, et al. 2016. Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model. Gynecol. Oncol. 141: 357–363.
32. Smith, J.A., A.B. Costales, M. Jaffari, et al. 2016. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. J. Oncol. Pharm. Pract. 22: 599–604.
33. Berger, J.L., A. Smith, K.K. Zorn, et al. 2014. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. Oncol. Targets Ther. 7: 1409–1413.
34. Desai, N. 2012. Challenges in development of nanoparticle-based therapeutics. AAPS J. 14: 282–295.
35. Toblli, J.E., G. Cao & M. Angerosa. 2015. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator. BioMetals 28: 279–292.
36. Porter, C.J.H., S.M. Moghimi, L. Illum, et al. 1992. The polyoxyethylene/polyoxypropylene block co-polymer Poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 305: 62–66.
37. European Medicines Agency. 2011. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. March 17, 2011. Accessed January 4, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdf.
38. U.S. Food and Drug Administration. 2013. Draft guidance on iron sucrose. November, 2013. Accessed January 4, 2017. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm297630.pdf.
39. Philipp, E., M. Braitsch, T. Bichsel, et al. 2016. Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability. Eur. J. Hosp. Pharm. 23: 22–27.
40. Crommelin, D.J.A., J.S.B de Vlieger, V. Weinstein, et al. 2014. Different pharmaceutical products need similar terminology. AAPS J. 16: 11–14.
41. European Commission. 2013. What you need to know about biosimilar medicinal products. Published Online First: 2013. Accessed January 4, 2017. http://ec.europa.eu/enterprise/sectors/healthcare/files/%0Bdocs/biosimilars_report_en.pdf.
42. Li, E.C. & J.G. Stevenson. 2015. Biosimilars—the time is now: challenges and opportunities for pharmacists (abstract). 50th ASHP Midyear Clinical Meeting and Exhibition. December 7, 2015.